2012
Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis
Meier P, Indermuehle A, Pitt B, Traupe T, de Marchi SF, Crake T, Knapp G, Lansky AJ, Seiler C. Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis. BMC Medicine 2012, 10: 62. PMID: 22720974, PMCID: PMC3386894, DOI: 10.1186/1741-7015-10-62.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary collateral circulationCoronary artery diseaseRisk ratioCoronary interventionCollateral circulationGood collateralizationCoronary collateralsStable coronary artery diseaseGood coronary collateralizationSummary risk ratiosSubgroup of patientsAcute myocardial infarctionRisk of restenosisIntracoronary pressure measurementsRandom-effects modelPoor collateralsAngiographic restenosisPrimary endpointArtery diseaseCoronary collateralizationRisk stratificationResultsA totalMyocardial infarctionSubgroup analysis
2011
Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy)
Choi SY, Maehara A, Cristea E, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Dressler O, Lansky AJ, Parise H, Mehran R, Mintz GS, Stone GW. Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy). The American Journal Of Cardiology 2011, 109: 455-460. PMID: 22118823, DOI: 10.1016/j.amjcard.2011.10.005.Peer-Reviewed Original ResearchConceptsMinimum stent areaST-segment elevation myocardial infarctionBare-metal stent useElevation myocardial infarctionAngiographic restenosisMyocardial infarctionStent areaIndependent predictorsStent usePrimary percutaneous coronary interventionStable coronary artery diseaseLumen areaMinimum stent cross-sectional areaDifferent antithrombotic regimensIntravascular ultrasound substudyPrimary percutaneous interventionStent cross-sectional areaPercutaneous coronary interventionCoronary artery diseaseAcute myocardial infarctionAverage lumen areaMinimum lumen areaIVUS minimum lumen areaAntithrombotic regimensAttenuated plaqueMINIMUM STENT AREA IS AN INDEPENDENT PREDICTOR OF ANGIOGRAPHIC RESTENOSIS AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN STEMI: A HORIZONS-AMI IVUS SUBSTUDY
Choi S, Maehara A, Mintz G, Lansky A, Witzenbichler B, Guagliumi G, Brodie B, Kellett M, Dressler O, Parise H, Mehran R, Stone G. MINIMUM STENT AREA IS AN INDEPENDENT PREDICTOR OF ANGIOGRAPHIC RESTENOSIS AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN STEMI: A HORIZONS-AMI IVUS SUBSTUDY. Journal Of The American College Of Cardiology 2011, 57: e1861. DOI: 10.1016/s0735-1097(11)61861-5.Peer-Reviewed Original ResearchPaclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction
Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, Lansky AJ, Nikolsky E, Mehran R, Stone GW. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. Circulation Cardiovascular Interventions 2011, 4: 130-138. PMID: 21364152, DOI: 10.1161/circinterventions.110.960245.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsTarget lesion revascularizationBare metal stentsHORIZONS-AMI trialDiabetic patientsDiabetes mellitusStent thrombosisMyocardial infarctionPercutaneous interventionIschemia-driven target lesion revascularizationMetal stentsAcute Myocardial Infarction trialHigh-risk diabetic patientsMyocardial Infarction trialPrimary percutaneous interventionInsulin-treated diabetesAcute myocardial infarctionAngiographic late lossComparable safety outcomesBinary restenosisHarmonizing OutcomesLesion revascularizationNondiabetic patientsAngiographic restenosis
2009
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, Lansky AJ. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial. JACC Cardiovascular Interventions 2009, 2: 205-214. PMID: 19463427, DOI: 10.1016/j.jcin.2008.12.011.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsMajor adverse cardiac event ratesAdverse cardiac event ratesSingle de novo lesionsMajor adverse clinical eventsStent late lumen lossEnd pointBinary angiographic restenosisCardiac event ratePrimary end pointSecondary end pointsDe novo lesionsRandomized multicenter trialAdverse clinical eventsStent late lossLate lumen lossNative coronary arteriesStent restenosis rateBare metal stentsAngiographic restenosisNovo lesionsCoronary angiographyMulticenter trialRestenosis rateLumen loss
2008
Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial.
Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. Journal Of Invasive Cardiology 2008, 20: 335-41. PMID: 18599890.Peer-Reviewed Original ResearchMeSH KeywordsAngiographyAngioplasty, Balloon, CoronaryBlood GlucoseCoronary Artery DiseaseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Drug-Eluting StentsFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedProspective StudiesRetrospective StudiesSingle-Blind MethodStentsTreatment OutcomeConceptsMajor adverse cardiovascular eventsPercutaneous coronary interventionDiabetic patientsAngiographic outcomesAdverse outcomesTaxus stentStent deploymentBare metal stent deploymentAdverse cardiovascular eventsMultivessel coronary diseaseTarget vessel revascularizationImproved clinical outcomesAngiographic restenosisCardiovascular eventsVessel revascularizationCoronary interventionCoronary diseaseGlycemic controlMultivessel stentingClinical outcomesDiabetic cohortElevated HbA1cLate lumenPatientsDiabetesTreatment of diffuse IN-stent restenosis with Drug-Eluting stents vs. intracoronary bEta-raDiation therapy: INDEED Study
Park SW, Lee SW, Bon Kwon Koo, Park DW, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Mori K, Lansky AJ, Mintz GS, Lee MM, Park SJ. Treatment of diffuse IN-stent restenosis with Drug-Eluting stents vs. intracoronary bEta-raDiation therapy: INDEED Study. International Journal Of Cardiology 2008, 131: 70-77. PMID: 18190986, DOI: 10.1016/j.ijcard.2007.09.003.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsIntracoronary brachytherapySES implantationMyocardial infarctionGroup IILate lossGroup IDiffuse ISRAngiographic restenosisSirolimus-eluting stent implantationEnd pointMore effective treatment modalitiesBare-metal ISRAdverse cardiac eventsPrimary end pointSecondary end pointsEffective treatment modalityIn-Stent RestenosisDrug-eluting stentsLesion revascularizationBaseline characteristicsCardiac eventsCardiac deathLower restenosisStent implantation
2007
Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial
Abizaid A, Chaves Á, Leon MB, Hauptmann K, Mehran R, Lansky AJ, Baumbach W, Shankar H, Muller R, Feres F, Sousa AG, Sousa JE, Grube E. Randomized, double‐blind, multicenter study of the polymer‐based 17‐β estradiol‐eluting stent for treatment of native coronary artery lesions: Six‐month results of the ETHOS I trial. Catheterization And Cardiovascular Interventions 2007, 70: 654-660. PMID: 17932898, DOI: 10.1002/ccd.21210.Peer-Reviewed Original ResearchConceptsStent volume obstructionIntravascular ultrasoundVolume obstructionI trialCoronary lesionsSingle de novo native coronary lesionsDe novo native coronary lesionsMean reference vessel diameterMajor adverse cardiac eventsNative coronary artery lesionsBinary angiographic restenosisAdverse cardiac eventsNative coronary lesionsPrimary end pointCoronary artery lesionsReference vessel diameterSix-month resultsStent late lossTreatment of patientsBare metal stentsMean lesion lengthLesion revascularizationAngiographic restenosisPrimary endpointSecondary endpoints
2006
Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials
Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-Eluting Stents in the Treatment of Intermediate Lesions Pooled Analysis From Four Randomized Trials. Journal Of The American College Of Cardiology 2006, 47: 2164-2171. PMID: 16750680, DOI: 10.1016/j.jacc.2006.01.068.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDrug-eluting stentsTarget vessel revascularizationIntermediate lesionsAngiographic restenosisMyocardial infarctionCardiac deathStent thrombosisDe novo coronary artery lesionsIntroduction of DESLate major adverse cardiac eventsEfficacy of DESNovo coronary artery lesionsBinary angiographic restenosisAdverse cardiac eventsCoronary artery lesionsCurrent treatment paradigmsTreatment of patientsIntermediate coronary lesionsBalloon-expandable stentsLower ratesEverolimus trialsRestenosis reductionTAXUS IVVessel revascularization
2005
Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and β‐brachytherapy for native vessel in‐stent restenosis (BETACUT): Results from a stopped randomized controlled trial
Schlüter M, Tübler T, Lansky AJ, Kähler S, Berger J, Mathey DG, Schofer J. Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and β‐brachytherapy for native vessel in‐stent restenosis (BETACUT): Results from a stopped randomized controlled trial. Catheterization And Cardiovascular Interventions 2005, 66: 320-326. PMID: 16216024, DOI: 10.1002/ccd.20517.Peer-Reviewed Original ResearchConceptsStandard balloonClinical outcomesCB angioplastyBalloon angioplastyStent restenosisInterim analysisMajor adverse cardiac eventsNative vesselsAdverse cardiac eventsOverall patient populationImmediate angiographic outcomeTreatment of choiceQuantitative coronary angiographyΒ-brachytherapyAngiographic restenosisBeta-radiation treatmentLesion revascularizationAngiographic outcomesCardiac eventsConsecutive patientsCoronary angiographyStudy armsIntracoronary brachytherapyPatient populationTreatment modalitiesGender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease
Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, Mehran R, Leon MB, Russell ME, Ellis SG, Stone GW, Investigators T. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. Journal Of The American College Of Cardiology 2005, 45: 1180-1185. PMID: 15837246, DOI: 10.1016/j.jacc.2004.10.076.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationPaclitaxel-eluting stent implantationIndependent predictorsStent implantationTaxus stentPaclitaxel-eluting Taxus stentElective coronary interventionTAXUS-IV trialOnly independent predictorCoronary artery diseaseOne-year ratesGender-based outcomesBare metal stentsLesion revascularizationMore hypertensionAngiographic restenosisRenal insufficiencyCoronary interventionUnstable anginaArtery diseaseHeart failureRestenosis rateLess smokingFemale genderLate lossImpact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL, Investigators F. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal Of Cardiology 2005, 95: 1-7. PMID: 15619385, DOI: 10.1016/j.amjcard.2004.08.054.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationAcute myocardial infarctionPrimary end pointDiabetic patientsNondiabetic patientsPrimary angioplastyDiabetes mellitusStent implantationMyocardial infarctionIschemic target vessel revascularizationEnd pointRoutine stent implantationAbciximab useComposite incidenceReperfusion modalityRoutine stentingAngiographic restenosisVessel revascularizationBalloon angioplastyImproved outcomesPatientsAngioplastyAbciximabDiabetesBeneficial effects
2004
Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER)
Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). American Heart Journal 2004, 147: 16-22. PMID: 14691413, DOI: 10.1016/j.ahj.2003.07.002.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationPrimary end pointDiffuse ISRPTCA groupBalloon angioplastyBalloon dilatationStent restenosisCoronary artery bypass graft proceduresIn-Stent Restenosis TrialStudy's primary end pointEnd pointHigh-pressure balloon dilatationRotational coronary atherectomySecondary end pointsBypass graft proceduresIntravascular ultrasound studyAcute luminal gainAdjunctive balloon dilatationIntimal hyperplasia areaAngiographic substudyAngiographic variablesLesion revascularizationRepeat stentingAngiographic restenosisAngiographic success
2003
Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis
Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, Mehran R, Dangas G, Moses JW, Stone GW, Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. The American Journal Of Cardiology 2003, 92: 1409-1413. PMID: 14675575, DOI: 10.1016/j.amjcard.2003.08.047.Peer-Reviewed Original ResearchConceptsMinimum lumen diameterVascular brachytherapyLesion lengthSegment restenosisAngiographic outcomesStent restenosisFinal minimum lumen diameterRandomized clinical trialsIndependent angiographic predictorsAngiographic restenosisPlacebo groupAngiographic predictorsAngiographic resultsMultivariable analysisNative coronariesVessel sizeClinical trialsLesion complexityVBT groupRestenosisLumen diameterSimilar reductionPlaceboGreater reductionLesionsVascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: Angiographic and clinical outcomes
Suntharalingam M, Laskey WK, Tantibhedhyangkul W, Lansky A, Teirstein P, Bass T, Silber S, Rutherford B, Wilmer C, Popma JJ, Kuntz R, Bonan R. Vascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: Angiographic and clinical outcomes. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 536-542. PMID: 12957267, DOI: 10.1016/s0360-3016(03)00537-6.Peer-Reviewed Original ResearchConceptsVessel revascularization ratePercutaneous coronary interventionDiabetic patientsNondiabetic patientsVascular brachytherapyNondiabetic counterpartsStent restenosisRevascularization ratesCoronary interventionLess target lesion revascularizationConventional percutaneous coronary interventionBinary angiographic restenosisAngiographic restenosis rateTarget lesion revascularizationReference vessel diameterComplex coronary lesionsMinimal lumen diameterStudy of patientsPercent diameter stenosisVessel diameterTreatment effectsBeta-Cath SystemBreslow-Day testLesion revascularizationAngiographic restenosisOutcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R, Investigators C. Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 42: 971-977. PMID: 13678914, DOI: 10.1016/s0735-1097(03)00911-2.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationRoutine stentingRoutine stent placementStent implantationStent placementPrimary percutaneous transluminal coronary angioplastyComposite adverse event rateLate Angioplasty Complications (CADILLAC) trialRoutine stent implantationAdverse event ratesTransluminal coronary angioplastyRelevant treatment modalitiesRate of deathCADILLAC trialControlled AbciximabEligible lesionsAngiographic restenosisVessel revascularizationComplications TrialCoronary angioplastyDiameter stenosisPTCA results
2002
Randomized Trial of 90Sr/90Y β-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis
Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Massullo V, Bass T, Henderson R, Silber S, von Rottkay P, Bonan R, Ho KK, Osattin, MPH A, Kuntz RE. Randomized Trial of 90Sr/90Y β-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis. Circulation 2002, 106: 1090-1096. PMID: 12196334, DOI: 10.1161/01.cir.0000027814.96651.72.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationStent restenosisPlacebo-treated patientsPrimary end pointCatheter-based treatmentIn-Stent RestenosisPlacebo sourcesStent thrombosesAngiographic restenosisClinical restenosisFirst multicenterIntracoronary radiationMyocardial infarctionPlacebo controlPatientsPrescribed doseRestenosisConventional treatmentIntracoronary catheterEnd pointDay 244PlaceboRevascularizationTreatmentIncidence
2001
Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis
Waksman R, Bhargava B, Chan R, Sherman W, Pisch J, Mintz G, Lansky A, Ahmed J, Ricci N, Liprie S. Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. Cardiovascular Revascularization Medicine 2001, 2: 63-68. PMID: 11340009, DOI: 10.1016/s1522-1865(00)00086-x.Peer-Reviewed Original ResearchConceptsIntracoronary gamma radiationTarget lesion revascularizationStent restenosisMyocardial infractionBaseline lesion lengthUnderwent bypass surgeryBinary restenosis rateEvent-free survivalNeointimal tissue proliferationInitial clinical trialsStent restenosis resultsSource wireLesion revascularizationRepeat PTCAAngiographic restenosisPrimary endpointRepeat revascularizationSecondary endpointsBypass surgeryRestenosis rateIntracoronary radiationProcedural successTherapeutic challengeClinical trialsNeointimal hyperplasiaLocalized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting
Leon M, Teirstein P, Moses J, Tripuraneni P, Lansky A, Jani S, Wong S, Fish D, Ellis S, Holmes D, Kerieakes D, Kuntz R. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal Of Medicine 2001, 344: 250-256. PMID: 11172151, DOI: 10.1056/nejm200101253440402.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryBrachytherapyCombined Modality TherapyCoronary DiseaseCoronary ThrombosisDose-Response Relationship, RadiationDouble-Blind MethodFemaleGamma RaysHumansIridium RadioisotopesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsRadiotherapy DosageSecondary PreventionStentsConceptsIridium-192 groupMyocardial infarctionLate thrombosisStent restenosisIridium-192Intracoronary irradiationTarget lesionsIntracoronary gamma radiation therapyMajor adverse cardiac eventsFrequency of restenosisOral antiplatelet therapyAdverse cardiac eventsComposite of deathPrimary end pointLate myocardial infarctionIntracoronary radiation therapyIncidence of deathRecurrence of restenosisGamma radiation therapyEligible patientsAngiographic restenosisAntiplatelet therapyPlacebo groupCardiac eventsCoronary angioplasty
2000
The PARAGON stent study: a randomized trial of a new martensitic nitinol stent versus the Palmaz-Schatz stent for treatment of complex native coronary arterial lesions
Holmes D, Lansky A, Kuntz R, Bell M, Buchbinder M, Fortuna R, O’Shaughnessy C, Popma J, Investigators F. The PARAGON stent study: a randomized trial of a new martensitic nitinol stent versus the Palmaz-Schatz stent for treatment of complex native coronary arterial lesions. The American Journal Of Cardiology 2000, 86: 1073-1079. PMID: 11074202, DOI: 10.1016/s0002-9149(00)01162-0.Peer-Reviewed Original ResearchConceptsStent minimal lumen diameterTarget vessel failureMinimal lumen diameterAngiographic restenosisPalmaz-SchatzLumen diameterPS stentEnd pointSignificant differencesAverage stent lengthBinary angiographic restenosisInfrequent adverse eventsPrimary end pointSecondary end pointsSmaller reference vesselsCoronary arterial lesionsNative coronary lesionsPrior bypass surgeryLong-term outcomesPalmaz-Schatz stentsPrior restenosisLesion revascularizationPercutaneous revascularizationBypass surgeryClinical restenosis